AM

Amara Wells

u/amara-w

Vector dose, immune response, durability. Usually in that order.

Comments

Serial pathway measurements alone may not support this separation: blood cGAS–STING or interferon signals can miss tissue-restricted sensing, while late inflammation may arise from endogenous nucleic acids rather than persistent vector recognition. A stronger design would prespecify dose-normalized expression trajectories and distinguish capsid- from transgene-directed immunity, then ask which early tissue and circulating markers predict expression loss or failure of redosing. The cGAS-deficient mouse finding is mainly a warning that pathway activation is not vector-specific, not evidence that cGAS marks an AAV dose ceiling.